Integra Net Debt from 2010 to 2025

IART Stock

USD 26.34 0.22 0.84%

Integra LifeSciences Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt is likely to outpace its year average in 2025. Net Debt is the total debt of Integra LifeSciences Holdings minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

1995-09-30

Previous Quarter

1.8 B

Current Value

1.8 B

Quarterly Volatility

513.9 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Integra LifeSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integra LifeSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 149.1 M, Interest Expense of 62 M or Total Revenue of 1.9 B, as well as many indicators such as Price To Sales Ratio of 4.18, Dividend Yield of 3.0E-4 or PTB Ratio of 3.52. Integra financial statements analysis is a perfect complement when working with Integra LifeSciences Valuation or Volatility modules.

Check out the analysis of Integra LifeSciences Correlation against competitors.

Latest Integra LifeSciences' Net Debt Growth Pattern

Below is the plot of the Net Debt of Integra LifeSciences Holdings over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Integra LifeSciences' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Integra LifeSciences' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Integra Net Debt Regression Statistics

	Arithmetic Mean	953,080,475
	Coefficient Of Variation	56.33
	Mean Deviation	470,346,291
	Median	1,158,698,000
	Standard Deviation	536,890,641
	Sample Variance	288251.6T
	Range	1.7B
	R-Value	0.89
	Mean Square Error	65960.6T
	R-Squared	0.79
	Slope	100,004,774
	Total Sum of Squares	4323773.4T

Integra Net Debt History

	2025	1.7 B
	2024	1.6 B
	2023	1.4 B
	2022	1.2 B
	2021	1.1 B
	2020	1.2 B
	2019	1.3 B

Other Fundumenentals of Integra LifeSciences

Net Debt To E B I T D A

Integra LifeSciences Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Term Debt	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.95	0.86	0.88	0.97	0.99	0.97	0.97	0.76	-0.01	0.84	0.96	-0.11	0.95	0.61	0.99	-0.62	0.87	0.87	0.18	-0.07	0.84	0.73	0.8	0.61
Total Stockholder Equity	0.98		0.87	0.89	0.85	0.94	0.94	0.97	0.93	0.77	0.01	0.82	0.88	-0.17	0.95	0.5	0.96	-0.48	0.78	0.9	0.17	-0.05	0.86	0.76	0.84	0.61
Net Debt	0.95	0.87		0.75	0.9	0.96	0.98	0.87	0.97	0.66	-0.06	0.79	0.99	0.0	0.9	0.7	0.96	-0.77	0.91	0.75	0.2	-0.11	0.73	0.59	0.63	0.57
Retained Earnings	0.86	0.89	0.75		0.77	0.79	0.82	0.88	0.75	0.91	-0.12	0.59	0.78	-0.41	0.8	0.5	0.83	-0.19	0.58	0.72	0.05	-0.18	0.7	0.89	0.86	0.79
Accounts Payable	0.88	0.85	0.9	0.77		0.94	0.88	0.81	0.87	0.58	-0.17	0.72	0.87	-0.1	0.89	0.6	0.89	-0.59	0.77	0.72	0.06	-0.21	0.73	0.55	0.56	0.56
Net Receivables	0.97	0.94	0.96	0.79	0.94		0.96	0.91	0.96	0.63	-0.02	0.83	0.95	-0.08	0.97	0.61	0.97	-0.66	0.85	0.82	0.18	-0.07	0.8	0.59	0.65	0.55
Total Liab	0.99	0.94	0.98	0.82	0.88	0.96		0.94	0.98	0.73	-0.02	0.82	0.99	-0.06	0.93	0.67	0.99	-0.7	0.91	0.83	0.18	-0.08	0.8	0.69	0.75	0.59
Total Current Assets	0.97	0.97	0.87	0.88	0.81	0.91	0.94		0.9	0.77	-0.03	0.79	0.91	-0.23	0.91	0.55	0.94	-0.48	0.81	0.84	0.05	-0.09	0.82	0.78	0.87	0.59
Intangible Assets	0.97	0.93	0.97	0.75	0.87	0.96	0.98	0.9		0.65	0.02	0.86	0.96	0.03	0.92	0.63	0.99	-0.76	0.92	0.85	0.27	-0.03	0.81	0.62	0.69	0.52
Short Term Investments	0.76	0.77	0.66	0.91	0.58	0.63	0.73	0.77	0.65		-0.12	0.5	0.68	-0.28	0.61	0.4	0.74	-0.15	0.52	0.68	0.05	-0.18	0.65	0.88	0.87	0.76
Short Term Debt	-0.01	0.01	-0.06	-0.12	-0.17	-0.02	-0.02	-0.03	0.02	-0.12		0.26	-0.03	0.33	0.04	0.18	0.0	-0.05	-0.01	-0.02	0.5	1.0	-0.1	-0.07	-0.05	-0.11
Common Stock	0.84	0.82	0.79	0.59	0.72	0.83	0.82	0.79	0.86	0.5	0.26		0.8	0.12	0.81	0.65	0.84	-0.66	0.88	0.87	0.26	0.21	0.86	0.52	0.65	0.37
Long Term Debt	0.96	0.88	0.99	0.78	0.87	0.95	0.99	0.91	0.96	0.68	-0.03	0.8		-0.05	0.9	0.71	0.97	-0.75	0.92	0.76	0.17	-0.08	0.73	0.64	0.68	0.57
Treasury Stock	-0.11	-0.17	0.0	-0.41	-0.1	-0.08	-0.06	-0.23	0.03	-0.28	0.33	0.12	-0.05		-0.19	-0.2	-0.04	-0.37	0.12	-0.1	-0.05	0.34	0.05	-0.32	-0.25	-0.24
Property Plant Equipment	0.95	0.95	0.9	0.8	0.89	0.97	0.93	0.91	0.92	0.61	0.04	0.81	0.9	-0.19		0.58	0.94	-0.56	0.78	0.83	0.26	-0.01	0.76	0.6	0.66	0.55
Current Deferred Revenue	0.61	0.5	0.7	0.5	0.6	0.61	0.67	0.55	0.63	0.4	0.18	0.65	0.71	-0.2	0.58		0.61	-0.6	0.72	0.46	0.44	0.16	0.34	0.44	0.38	0.42
Good Will	0.99	0.96	0.96	0.83	0.89	0.97	0.99	0.94	0.99	0.74	0.0	0.84	0.97	-0.04	0.94	0.61		-0.67	0.88	0.86	0.2	-0.06	0.83	0.7	0.76	0.6
Net Tangible Assets	-0.62	-0.48	-0.77	-0.19	-0.59	-0.66	-0.7	-0.48	-0.76	-0.15	-0.05	-0.66	-0.75	-0.37	-0.56	-0.6	-0.67		-0.85	-0.47	-0.31	-0.03	-0.46	-0.09	-0.19	-0.05
Long Term Debt Total	0.87	0.78	0.91	0.58	0.77	0.85	0.91	0.81	0.92	0.52	-0.01	0.88	0.92	0.12	0.78	0.72	0.88	-0.85		0.77	0.14	-0.06	0.78	0.52	0.63	0.37
Capital Surpluse	0.87	0.9	0.75	0.72	0.72	0.82	0.83	0.84	0.85	0.68	-0.02	0.87	0.76	-0.1	0.83	0.46	0.86	-0.47	0.77		0.23	-0.08	0.93	0.67	0.8	0.52
Deferred Long Term Liab	0.18	0.17	0.2	0.05	0.06	0.18	0.18	0.05	0.27	0.05	0.5	0.26	0.17	-0.05	0.26	0.44	0.2	-0.31	0.14	0.23		0.49	-0.06	0.04	-0.04	0.09
Short Long Term Debt	-0.07	-0.05	-0.11	-0.18	-0.21	-0.07	-0.08	-0.09	-0.03	-0.18	1.0	0.21	-0.08	0.34	-0.01	0.16	-0.06	-0.03	-0.06	-0.08	0.49		-0.16	-0.14	-0.11	-0.15
Long Term Investments	0.84	0.86	0.73	0.7	0.73	0.8	0.8	0.82	0.81	0.65	-0.1	0.86	0.73	0.05	0.76	0.34	0.83	-0.46	0.78	0.93	-0.06	-0.16		0.63	0.8	0.47
Net Invested Capital	0.73	0.76	0.59	0.89	0.55	0.59	0.69	0.78	0.62	0.88	-0.07	0.52	0.64	-0.32	0.6	0.44	0.7	-0.09	0.52	0.67	0.04	-0.14	0.63		0.92	0.85
Net Working Capital	0.8	0.84	0.63	0.86	0.56	0.65	0.75	0.87	0.69	0.87	-0.05	0.65	0.68	-0.25	0.66	0.38	0.76	-0.19	0.63	0.8	-0.04	-0.11	0.8	0.92		0.64
Capital Stock	0.61	0.61	0.57	0.79	0.56	0.55	0.59	0.59	0.52	0.76	-0.11	0.37	0.57	-0.24	0.55	0.42	0.6	-0.05	0.37	0.52	0.09	-0.15	0.47	0.85	0.64

Click cells to compare fundamentals

About Integra LifeSciences Financial Statements

Integra LifeSciences shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Integra LifeSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Integra LifeSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Integra LifeSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	1.6 B	1.7 B
Net Debt To EBITDA	4.62	2.31

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Integra Stock Analysis

When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Integra Net Debt from 2010 to 2025

Latest Integra LifeSciences' Net Debt Growth Pattern

Integra Net Debt Regression Statistics

Integra Net Debt History

Other Fundumenentals of Integra LifeSciences

Integra LifeSciences Net Debt component correlations

About Integra LifeSciences Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Integra Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY